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Abstract  
 
The apicomplexan parasite Toxoplasma gondii was discovered a little over one hundred years 
ago and was soon recognized as a pathogen responsible for congenital infection. But detailed 
understanding of its epidemiology emerged only after 1970 with the discovery of its life 
cycle. In the last ten years, high resolution molecular tools have allowed the characterisation 
of various strain types with different virulence patterns, and current studies are exploring the 
distribution of these different genotypes. In parallel, sophisticated diagnostic tools have been 
developed and awareness of disease burden has led some European countries with high 
prevalence rates to implement screening of pregnant women. In this article, the screening 
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options and therapies used to prevent congenital toxoplasmosis are dissected in the light of 
recent data from cohort studies and other epidemiological data. 
 
1 Introduction 
 
Infection with the protozoan Toxoplasma gondii is one of the most frequent parasitic 
infections worldwide. This obligate intracellular parasite was first described in the gondi, a 
rodent from North Africa, by Nicolle and Manceaux in 1908 [1], and was subsequently 
recognized as the agent of a widespread zoonosis involving humans as well as virtually all 
warm-blooded animals and birds. However, it was several decades before its entire life cycle 
was eludicated in the late 1960s [2-4], with the demonstration of the cat as the definitive host 
responsible for oocyst shedding through feces and contamination of intermediate hosts.  
 
Significant steps towards understanding and control of human infection include the first 
reports of cases of congenital toxoplasmosis in 1939 [5], the development of the first 
serologic test by Sabin & Feldman in 1948, the recognition, in the mid-1970s, that past 
infection could reactivate in immunocompromised patients [6] and the development of 
prevention policies in some European countries to reduce the burden of congenital 
toxoplasmosis. During the last decade, the development of new genotyping tools and the 
multiplication of field studies have increased comprehension of the phylogenetic evolution of 
T. gondii globally [7] and of virulence associated with some specific genotypes [8].   
This article aims to provide an update on the epidemiology of toxoplasmosis and to 
summarise approaches to management of toxoplasmosis during pregnancy and childhood. 
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2 New insights into the epidemiology of toxoplasmosis 
 
2.1 Life cycle of Toxoplasma gondii and sources for human infection 
 
There are three infective stages of T. gondii, of which the first two are found in intermediate 
hosts including humans: i) the rapidly dividing tachyzoite stage, the disseminating form 
which is capable of invading all nucleated cells and thus all organs, ii) the quiescent 
bradyzoite form, present typically in hundreds within tissue cysts, which can persist lifelong 
after infection, mostly in muscles, retina and brain, and iii) the sporozoite-containing oocyst, 
generated after sexual replication in the intestinal tract of the definitive hosts, i.e. cats and 
other Felidae, and massively contaminating the environment (Figure 1). More details can be 
found in recent reviews [9-10]. Oocysts are responsible for direct infection of humans and 
herbivores/rodents/birds, usually through contamination of food and pastures / soil, 
respectively. Secondarily, mammals and birds are themselves a potential source of 
contamination for carnivores through ingestion of cyst-containing tissues, and the parasite 
can propagate in wildlife through a dynamic involving carnivore-to-carnivore or herbivore-
to-carnivore transmission. 
All 3 stages are susceptible to heating above 65°C and thus are killed by cooking (cyst-
containing meat, vegetables contaminated with oocysts), or pasteurization (milk 
contaminated with tachyzoites). However, they are differently affected by freezing. Indeed, 
whereas cysts are usually killed by freezing at -20°C for at least 15 days [11-12], oocysts can 
survive at -10 to -20°C for several months [13-14].  
 
Consequently, humans can become infected in various ways. Oral contamination can occur 
through direct ingestion of oocysts after consumption of raw vegetables or contaminated 
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water, or through dirty hands after gardening, outdoor recreation activities or cat contact. 
Secondly, the widespread distribution of the parasite in animals, as intermediate hosts 
supporting asexual replicating stages, offers a wide range of opportunities for human 
infection through ingestion of undercooked meat (Figure 1). Another way of acquiring 
Toxoplasma infection through cysts is by transplantation of an organ from an infected donor 
to an uninfected recipient. Finally, vertical transmission can follow maternal primary 
infection during pregnancy, by transplacental transfer of tachyzoites during blood stream 
dissemination.  
 
2.2 Prevalence of toxoplasmosis 
 
2.2.1 Prevalence in animals  
 
Toxoplasma infection has been described in more than 350 host species, mammals and birds, 
the vast majority of them living in a wild environment [15]. Prevalence in these intermediate 
hosts depends on the presence of felids in their environment. The processes promoting 
infection in animal populations are highly complex and involve the interaction of various 
characteristics: i) climate, as areas with dry and hot climates are unfavourable to oocyst 
survival and are associated with lower prevalence in wild animals, while higher prevalence is 
observed in humid tropical countries [13], ii) the susceptibility of the host species to 
Toxoplasma infection, and iii) the host species’ diet and feeding behaviour [9]. 
Prevalence among animals bred for meat-production varies according to the geographical 
area, but also to the type of breeding. Rates of Toxoplasma infection in livestock have been 
considerably reduced in areas with intensive farm management, adequate hygiene and 
confinement avoiding the presence of rodents, birds, and cats, and feeding meat-producing 
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animals on sterilized food [16]. Thus, seroprevalence in slaughter pigs is now <5% in most 
industrialized countries [17]. Prevalence in meat producing animals kept on pasture, such as 
sheep, goats and horses remains unchanged. Actually, sheep, rather than pigs, are the main 
source of infected meat in southern European countries, with a prevalence increasing from 
17-22% in lambs to 65-89% in adult [18]. Seropositivity reported in goats varies from 4-77% 
[15], while it is generally lower in horses [19]. 
 
2.2.2 Prevalence in humans 
 
Estimates indicate that approximately 25 to 30% of the world human population is infected 
by Toxoplasma [20]. The prevalence varies widely between countries (from 10 to 80%) and 
often within a given country and even between different communities living in a same region 
[21]. Low seroprevalence (10-30%) is observed in North America, in South East Asia, in 
Northern Europe, and in Saharan countries of Africa. Moderate prevalence (30-50%) is found 
in countries of central and southern Europe, and high prevalence in South America and in 
tropical African countries. As in animals, many factors can affect seroprevalence in humans. 
Climatic factors affecting survival of oocysts in the environment, and hence infection of 
meat-producing animals, are naturally important. But many other factors may explain large 
variations in human seroprevalence, such as cooking habits, socio-economic levels, social or 
cultural habits, quality of water and sanitation coverage. Seroprevalence has declined over 
recent decades in most industrialized countries, probably as a result of multiple factors 
including improved socioeconomic levels, improvements in hygiene, changes in farming 
systems, consumption of frozen meat, and feeding of cats with sterilized food. For example, 
in France, the seroprevalence in pregnant women was about 80% in the early sixties, and 
declined to 54% and 44% in two national surveys in 1995 and 2003, respectively, while at the 
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same time the average age of first pregnancy increased [22]. From the 2003 national survey, 
the mean infection rate during pregnancy was estimated to be 6-7 per 1000 seronegative 
pregnant women [23]. The incidence at birth was about 3 per 10,000 live births in 2007 in 
France [22], which is in the same range as incidence rates reported in other European 
countries, such as Denmark (2.1/10,000 live births) and Switzerland (4.3/10,000 live births), 
but is higher than that reported in Sweden (0.73/10,000) and in a pilot study in 
Massachussetts (1/10,000) [24] and lower than in Brazil (6/10,000) [25].  
 
2. 3 Genotype distribution and virulence: implications for human disease 
 
Although one single parasite species is responsible for toxoplasmosis in humans and animals, 
it has been shown that from the 1990s, clinical isolates from Europe and USA could be 
divided into three major genotypes: types I, II and III, equivalent to clonal lineages, stable in 
time and space [26-28]. However, multilocus and multi-chromosome genotyping of isolates 
from other continents revealed a much more complex population structure with a greater 
genetic diversity likely reflecting frequent exchanges between hosts and recombination of 
isolates during the sexual life cycle within the definitive hosts [29]. This led to the generation 
of recombinant isolates (I/II, I/III or II/III), but also to new clonal haplogroups (12 are now 
described in the world including the three initial types I, II, III), and in some areas, 
particularly in South America, to atypical genotypes with many unique polymorphisms which 
cannot be clustered into one of these haplogroups. In Europe, type II strains markedly 
predominate both among humans and animals [30-31], and are isolated in more than 90% of 
congenital infections in France. Other clonal lineages are occasionally (type III) or 
exceptionally (type I) described in Europe. The exceptional isolation of atypical strains in 
France can be related to travels in South America or consumption of imported meat [32]. The 
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epidemiological picture is relatively similar in North America, where type II strains also 
predominate [27], but recent data suggest a higher prevalence of atypical strains in North 
America and another clonal haplogroup (haplogroup 12) has recently been identified [33]. By 
contrast, atypical genotypes largely predominate in South America, whereas type II isolates 
are very rare. [34]. In Africa, clonal lineages known as Africa 1-3 haplogroups coexist with 
type II and III lineages [35]. Data from Asia are scarce, but some studies reveal a more 
limited genetic diversity than in South America, with the widespread presence of a clonal 
lineage in China [36].  
 
It has long been thought that the immune background of the patient, as well as the trimester 
of pregnancy at maternal infection, were the key explanatory factors for the severity of 
clinical signs in adults and in the foetus, respectively. In the light of recent knowledge of 
genotype strains, this interpretation needs to be somewhat modified. The fact that infection is 
usually asymptomatic when it occurs in an immunocompetent subject is not questioned in 
Europe and North America, but recent experience from French Guyana using new genotyping 
tools, shows that severe and even lethal toxoplasmosis can be observed in immunocompetent 
patients infected with atypical strains [37]. Similar observations have been made in Brazil, 
where cases of retinochoroiditis, including clusters [38], have been repeatedly described in 
the context of primary toxoplasmosis [39], an event which has now also been described in 
Europe, but to a far lesser extent [40]. The pathophysiology of acquired toxoplasmosis during 
pregnancy should be also revised. The common notion is that the frequency of transplacental 
transmission increases with the age of gestation. That the degree of foetal damage is 
dependent on gestational age at maternal infection cannot not denied, but recent observations 
have also shown that: i) re-infection with an atypical strain of a previously infected woman 
can result in congenital transmission [41], and ii) the rate of severe congenital  infection is 
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higher when women were infected with an atypical or recombinant strain than with a type II 
strain. Indeed, cumulative data (2006-2011) from the French national network of the Centre 
National de Référence de la Toxoplasmose show that about 92% of congenital infections are 
due to Type II strains, of which 84% are asymptomatic infections, whereas 83% of infections 
with atypical or recombinant genotypes are symptomatic (https://www. chu-
reims.fr/professionnels/cnr-toxoplasmose-1). 
 
3 Prevention of toxoplasmosis during pregnancy 
 
3.1 Actualization of primary prevention measures 
 
Prevention of congenital infection relies primarily on hygienic measures to avoid infection. 
Targeted counselling could be directed towards seronegative women, if serologic screening is 
routine. A written document spelling out the various recommendations should be given and 
explained for better compliance. Prevention messages include hygienic measures related to 
cats, the importance of cooking meat well and washing vegetables to be eaten raw 
thoroughly, as well as of hand washing (Table 1). Drinking water has recently emerged as a 
new risk factor in some countries including Brazil, India and Canada [42-44], depending on 
the source of the water supply network (surface or ground water) and on the sanitary level or 
the use of well water. In addition, an American study describes possible infection from 
ingestion of water during outdoor recreational activities [45], a widespread hobby in North 
America, which could partly explain high rates of infections of unknown origin [46]. 
Therefore, the consumption of mineral or sterilized water could be recommended for 
pregnant women, as well as care with regard to water-based activities in lakes or rivers. In 
view of recent information about virulent strains, it is likely that these hygienic measures 
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could be also beneficial for seropositive pregnant women who travel in South America or in 
Africa. 
 
3.2 Serologic screening 
 
Serologic screening is another part of primary prevention, which focuses on the foetus. 
Indeed, it is based on the early detection of infection in the mother to allow early treatment 
aiming to reduce vertical transmission, and any foetal sequelae. 
Such screening has been performed in France for 20 years and involves initial serology 
during the first trimester of pregnancy followed by monthly testing in seronegative women. 
Other countries also have screening policies (Austria, Belgium, Italy, Lithuania, 
Slovenia)[47], but the frequency of follow up serologic testing varies from one to three 
monthly. Some countries do not recommend screening (United Kingdom, Norway, Finland), 
arguing either that seroprevalence is too low for cost effectiveness, or that maternal stress in 
the case of diagnosis by detecting seroconversion or that foetal risk associated with 
amniocentesis are unacceptable. Other countries have no specific recommendations 
concerning prenatal screening [48]. 
 
4 Reducing the burden of congenital toxoplasmosis 
 
4.1 Prenatal treatment 
 
4.1.1 Treatment schemes and management of pregnancy surveillance 
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Serologic screening offers the opportunity to treat the mother as soon as the primary infection 
is detected, and to propose prenatal diagnosis, the negative predictive value of which is at 
least 90% [49-50] when using sensitive PCR targets, thus allowing reassurance of the couple 
if parasitologic detection in amniotic fluid is negative. On the other hand, when foetal 
infection is diagnosed, it prompts changing standard spiramycin treatment (3 MIU/tid) to a 
pyrimethamine-sulphadiazine combination which is considered to be more effective in 
reducing foetal sequelae. Regular monthly follow-up ultra-sound scans are also usually 
scheduled throughout the rest of the pregnancy. 
 
4.1.2 Does prenatal treatment reduce vertical transmission? 
 
The question of treatment efficacy is contentious. Several multicentre studies and meta-
analyses have yielded contradictory and possibly biased results. One problem is the frequent 
absence of an untreated control group of approximately the same size as the treated group in 
clinical practice. Participating centres which include patients in studies and case series are 
generally engaged in the diagnosis of congenital toxoplasmosis and usually prescribe 
antenatal treatment to mothers. Where local clinical equipoise is absent, an untreated control 
group is difficult to justify ethically. Assembling control group data from patients from 
countries where prenatal screening and treatment is not implemented, but where infected 
newborns are diagnosed through postnatal screening results in important gaps in the data such 
as the age of gestation at maternal infection, which is a determinant of transmission as well as 
severity of foetal injury and needs to be comparable between groups. Among treated patients, 
the dating of maternal infection can usually be achieved more or less precisely by 
retrospective analysis of stored sera taken during pregnancy. Last but not least, studies must 
take into account the delay to treatment after maternal infection. This also depends on the 
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frequency of serologic screening. Monthly screening as performed in France results in rapid 
implementation of treatment, whereas 3-monthly testing may result in delays and potentially 
reduced efficacy.  
The consequential difficulties are evident in the attempts made to date to synthesise the 
evidence. The first meta-analysis in the field [51] included 9 papers and did not find any 
effect of treatment in reducing vertical transmission, but with important limitations as 
discussed, namely: i) the lack of an untreated control group, ii) the lack of sufficiently long 
follow-up of newborns to rule out congenital infection with a high degree of confidence, and 
iii) uncertainty concerning the delay between maternal infection and onset of treatment. 
Similar conclusions were drawn from a European multicentre study [52] which included 
1,208 mothers of whom only 106 were untreated controls (<10%). The authors acknowledged 
a lack of power and the weakness that data were heterogeneous (differences between 
treatment regimens and variable initiation delays depending on serological screening policies. 
Indeed, these were compounded as the median delay for treatment with spiramycin was about 
4 weeks, whereas it was >8 weeks with the potentially more effective pyrimethamine – 
sulphadiazine regimen).  
 
In 2007, a larger systematic review (SYROCOT study) included 26 cohorts from USA and 
Europe, reporting 1,745 mothers, of whom 307 were not treated (18%), and 691 infected 
newborns [53]. The authors concluded that transmission was reduced if treatment was started 
less than 3 weeks after infection, when compared to a delay of greater than 8 weeks (p<0.05), 
but found no difference between treatment spiramycin and pyrimethamine – sulphadiazine 
treatment regimens.  
Finally, a recent French study addressed indirectly the efficiency of prenatal management on 
the burden of disease, by analysing the impact of the implementation of screening policy.  
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The authors found that the transmission rate was higher in the period 1987-1991, i.e. before 
the implementation of mandatory monthly serologic screening, than in the period 1992-2008 
[54].  
 
4.1.3 Does prenatal treatment reduce foetal sequelae? 
 
To address this question, the SYROCOT study [53] included 1,438 mothers and 550 infected 
newborns from Europe to avoid possible bias due to more virulent strains circulating in 
America. One hundred and five infants (19%) had clinical manifestations (14% with ocular 
lesions, 9% with intracranial lesions). The odds of cerebral manifestations decreased as 
expected with the age of gestation, but although the odds ratio appeared lower with treatment, 
the 95% confidence limits crossed 1 and no clear effect of type and timing of treatment was 
observed. As there were missing data in 15%, this adds further uncertainty regarding 
outcome. What this study gains in size and thus power it loses through heterogeneity of data. 
 
For several other studies which yielded concordant conclusions as to the efficacy of prenatal 
treatment in reducing cerebral sequelae, it tends to be the other way around. In a prospective 
study, Gras et al. [55] followed 255 live-born infected infants and observed that any prenatal 
treatment within 4 weeks of seroconversion was associated with reduced risk of intracranial 
lesions. Another recent European survey [56] including 293 infected foetuses (189 treated, 
284 born alive) from 14 centres with 4 years median follow-up, found that any treatment was 
associated with reduced risk of serious neurological sequelae or death (SNSD). There was no 
apparent difference in outcome comparing spiramycin with pyrimethamine – sulphadiazine, 
but again the median interval to starting spiramycin was about 4 weeks, whereas for 
pyrimethamine – sulphadiazine it was greater than 8 weeks. Point estimates for risk of SNSD 
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in this study following seroconversion at 10 weeks of gestation, were 25.7% and 60% when 
mothers were treated or untreated, respectively. An association between early treatment (less 
than 4 weeks after maternal infection) and reduced foetal damage or sequelae has also been 
reported in smaller studies [57-58].  
The question of the most appropriate treatment is still a matter of debate, since no study 
showed a clear-cut difference between spiramycin and pyrimethamine-sulfonamide 
treatment. However, in the recent study of Wallon et al. [54], it appears that a change in the 
treatment guidelines, i.e. alternating spiramycin and pyrimethamine – sulphadiazine for 3-
week periods switched to continuous pyrimethamine – sulphadiazine, led to a highly 
significant reduction of clinical signs in infected children. 
The impact of prenatal treatment on ocular sequelae is less clear and more difficult to 
evaluate. Eye lesions can develop years after birth, whether children have been treated 
antenatally or not. What may differ is the frequency of recurrence of episodes or the severity 
of the lesions. Although several studies showed no effect of prenatal treatment on eye 
sequelae [53, 55], Kieffer et al. [59] reported that the incidence of ocular lesions below 2 
years of age was associated with maternal treatment delayed to more than 8 weeks after 
infection and with the presence of intracerebral calcifications at birth. 
It is of interest to note that the incidence of symptomatic congenital toxoplasmosis in France 
was estimated to be 0.34 cases per 10,000 live births (about 11% of infected neonates) in 
2007 and subsequently  whereas, despite much lower seroprevalence in England (about 10% 
compared to 44% in France),  the equivalent incidence rate has been estimated to be rather 
similar (0.16 per 10,000 live births).[60] Although there may be differences in ascertainment 
or other biasing factors to account for this, it might also reflect the impact of systematic 
screening and treatment of women with acquired toxoplasmosis during pregnancy in France 
which is not done in England. 
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A recent US study addressed the societal cost of congenital toxoplasmosis using a decision-
analytic economic model and evaluating a prenatal screening system similar to that 
implemented in France (maternal serologic screening, prenatal diagnosis and treatment) and 
concluded that, even in a country like the USA with a very low infection rate of 1 per 10,000 
live births, universal prenatal screening would be cost-saving [61]. This study estimated the 
costs of mild visual loss and of severe toxoplasmosis to be 500,000 US$ and 2.7 million US$, 
respectively. 
 
4.2 Postnatal treatment 
 
4.2.1 Treatment regimens 
 
Treatment of congenitally infected children consists of a combination of pyrimethamine and a 
sulphonamide (sulphadiazine or sulphadoxine). Two treatment regimens are widely used, 
sometimes with minor modifications in dose or length (Table 2). In case of severe 
abnormalities at birth, including neurological signs and/or >1 ocular lesions and/or >3 
intracerebral calcifications, the higher dose longer regimen is recommended (Table 2). Since 
these treatments can have bone marrow toxicity, regular blood counts should be performed, at 
least twice monthly. Neutropenia is more frequently observed in patients treated with 
pyrimethamine-sulphadiazine [62], sometimes leading to interruption of therapy for about 2 
to 3 weeks until neutrophil counts recover above 1,000/mL.  
 
4.2.2 Does postnatal treatment reduce the frequency and severity of clinical 
manifestations during childhood? 
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Ideal studies to answer this question are also difficult to conduct. Not only would infected 
infants need to be identified in a timely fashion perhaps by postnatal screening but they 
would also have to be randomised to treatment or placebo which, in the absence of clinical 
equipoise is once again ethically unacceptable. In addition, the effectiveness of postnatal 
treatment could be affected by whether antenatal treatment had been used. In practice, the 
best that can be done is to draw information from retrospective cohort studies. These provide 
two distinct pictures of disease, one from Northern America and the other from Europe. 
 
4.2.2.1 The US cohorts 
 
In Northern America, where no prenatal screening is implemented, most cases are diagnosed 
on the basis of clinical signs which lead to referral to a specialist centre. Asymptomatic cases 
remain for the most part undetected and resulting in a probable overestimation of typical 
disease severity, except in centres or states (Massachussetts, New Hampshire, New England, 
Chicago IL) where local postnatal screening schemes were implemented in the 1990s. 
 
In spite of this partial epidemiological view, large longitudinal studies performed in these 
centres with the participation of the Reference Centre Toxoplasma Serology Laboratory (Palo 
Alto, CA, USA) have provided a consistent body of data comparing clinical outcomes of 
children treated in early infancy and untreated infants from historical series. What emerged 
from these cohort studies is that better neurologic and developmental outcomes were 
observed in children who were treated for one year than in untreated children [24, 63-65], 
notably in terms of neurological signs, seizures, IQ, vision, or occurrence of new eye lesions. 
In older series, untreated infants, though asymptomatic at birth, developed high rates of 
ocular lesions (92%) or neurologic sequelae (12%) [66], or suffered from recurrent episodes 
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of retinochoroiditis (72%), despite spot treatment at time of diagnosis and at each recurrent 
lesion [67]. Compared to this poor outcome, a striking improvement was observed in cohorts 
benefiting from local postnatal screening policy and treatment, as, for example, the New 
England initiative, who reported that only 10% of infants treated for one year after birth, 
developed recurrent retinal lesions.  
 
Together, these findings suggest that postnatal treatment greatly improves the clinical 
outcome in children who did not receive prenatal treatment, supporting the case for screening 
at birth to diagnose infected infants. However, recent observations concerning the 
epidemiology of parasite strains in North America suggest that the high disease burden there 
could be due not only to the absence of prenatal management or postnatal treatment, but also 
to the circulation of type non-II strains, which may be more virulent [68]. 
 
4.2.2.2 The European cohorts 
 
In most European studies, a large proportion of cases received prenatal treatment, thus the 
respective effects of prenatal and postnatal treatments are hard to distinguish. Several large 
series report a low rate of clinical symptoms at birth. Of 325 infants treated for 1 year, 
Wallon et al. [69] reported only 3% of ocular lesions at birth and 69% of them had normal 
visual acuity at age 6. Similar results were observed in another French study, with 8.7% 
having eye lesions at birth and about 10% during a mean follow-up of 4 years [70]. An 
interesting point in terms of prognosis was the observation that symptomatic children 
developed eye lesions at a young age, as 75% and 92% of them  had retinochoroiditis at age 
<2 and at age <5, respectively, indicating that late occurrence of eye lesion is scarce in 
treated children. In a multicentre study including infants from France, Austria, Italy, Poland, 
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and Scandinavia, the authors reported an 18% rate of ocular disease [71]. The risk of eye 
lesions by the age of 4 years was higher in children with neurologic sequelae, intracerebral 
calcifications or hepatosplenomegaly, an association previously reported by Kieffer et al. 
[59]. In contrast, children with no sign of retinochoroiditis at 4 months of age had a low risk 
of developing eye lesions by the age of 4 years [71]. Therefore, it has been proposed that 
children with no clinical signs at birth and normal foetal ultrasound, i.e. about 80% of live 
born infected infants in Europe, could be offered short course treatment (3 months) instead of 
1 year [71], with yearly fundus examinations. Conversely, children with ocular lesions at 
birth or otherwise at high risk for developing retinochoroiditis, i.e. with foetal ultrasound 
abnormalities or neurologic impairment, should receive full course treatment along with 
repeated ocular examination [72]. However, it must be underlined that these adapted 
recommendations should be validated in a randomized clinical trial. While they may be 
pertinent in Europe where low virulence Type II strains largely predominate, they cannot be 
applied to the American continent, particularly South America. A national clinical trial is 
underway in France to evaluate the equivalence of 3-month and 12-month treatment in 
asymptomatic infected neonates.  
 
4.3 Concluding remarks and synthesis for clinical practise 
 
The disease burden of congenital toxoplasmosis has probably decreased in European 
countries where prevalence was high, thanks to the implementation of prevention policies. 
Today, some studies are examining the usefulness of screening and prolonged follow-up. The 
efficacy of prevention combined with the predominance of low virulent strains may have 
minimized disease burden in Europe as compared to South America, but one should take care 
not to underestimate the benefits of integrated management of toxoplasmosis. Shorter 
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postnatal treatment schemes could be proposed in the future, at least for asymptomatic 
newborns. 
 
5 Conclusion 
 
Great advances have been achieved in the fields of diagnosis and epidemiology of 
toxoplasmosis. It appears now that clinical aspects of toxoplasmosis must be unravelled in the 
light of Toxoplasma genotypes and of their geographical distribution. Primary prevention 
measures now need to take the risks associated with water consumption and travel into 
consideration. Prenatal screening has been challenged after studies questioning the efficacy of 
prenatal treatment, but more recent articles suggest that treatment reduces severe sequelae at 
birth. The impact of such screening policies varies with the seroprevalence which is very 
different among countries, thus the cost-benefit ratio must always be carefully evaluated. In 
countries where postnatal screening has been implemented, symptomatic children should be 
treated to prevent aggravation of symptoms and neurologic deterioration. The use of full or 
abbreviated treatment regimens for asymptomatic infected children is currently under debate 
in Europe, but ongoing studies should resolve this issue. 
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Figure 1: Sources of human Toxoplasma infection 
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Table captions 
 
Table 1 Primary measures to prevent Toxoplasma infection 
 
Table 2 Treatment regimens widely used for congenital toxoplasmosis 
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Table 1  
Action or situation  Prevention measures 
Cat contact Wash hands carefully after stroking a cat 
Wear gloves when changing the cat litter 
Change the litter frequently and wash the tray with 
hot water (>60°C) 
Avoid keeping the litter in the kitchen 
Meals  Cook meat well or stew  
Avoid microwave cooking of meat 
Avoid raw vegetables at restaurants  
Avoid raw shellfish 
Preparation of meals Wash vegetables, fruits and herbs eaten raw, 
thoroughly especially if they grow close to the ground 
Wash hands, knives, any containers and table 
thoroughly after raw meat manipulation or cutting 
Water Drink bottled or boiled or sterilised rather than 
untreated tap water in particular in countries with 
surface water supply and in tropical countries 
Gardening & outdoor activities  Wash hands thoroughly and brush nails after any 
outdoor activities in contact with soil 
Wear gloves for gardening 
Avoid ingestion of water during recreation activities 
in lakes or rivers 
- 30 - 
 
Table 2  
Treatment options Asymptomatic or mildly 
affected child 1 
Severely affected child 2 
Pyrimethamine  
 
and 
 
Sulphadiazine  
and 
folinic acid 
 
1 mg/kg/day (2 months)  
then 0.5 or 1 mg/kg/day   
3 times/week (10 months) 
 
100 mg/kg/day (1 year)  
50 mg/wk 
1 mg/kg/day (6 months) 
then 0.5 or 1 mg/kg/day)      
3 times/week (6 months) 
 
100 mg/kg/day (1 year)  
50 mg/wk 
Pyrimethamine /  
sulphadoxine (25/500 mg) 
(Fansidar®)  
and 
folinic acid 
 
1/4 tab /5 kg every 15 days) 
(1.25 mg/kg & 25 mg/kg) 
(1-2 years) 
 
50 mg once/week 
 
1/4 tab /5 kg every 7 days)  
(1.25 mg/kg & 25 mg/kg) 
(1-2 years) 
 
50 mg once/week 
 
1 
 1 ocular lesion and/or <3 intracerebral calcifications 
2
 neurological signs and/or >1 ocular lesion and/or >3 intracerebral calcifications 
 
